Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuko Mishima

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
Blood|May 20, 2017
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluationNaoko Tsuyama, Seiji Sakata, Satoko Baba, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 9, 2017
Efficacy of chemotherapy in extremely elderly patients with diffuse large B-cell lymphomaAnna Takahashi, Yuko Mishima, Masahiro Yokoyama, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 28, 2005
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify]Hisakazu Nishimori, Shunji Takahashi, Eijiro Nagasaki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 25, 2010
[Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I]Kyoko Ueda, Masahiro Yokoyama, Hiroaki Asai, et al.
International Journal of Hematology|December 28, 2022
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignanciesWataru Munakata, Kiyoshi Ando, Masahiro Yokoyama, et al.
Scientific Reports|August 22, 2023
Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapyYuko Shirouchi, Noriko Nishimura, Yuko Mishima, et al.
British Journal of Haematology|October 28, 2017
Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5<sup>+</sup> DLBCLYuko Mishima, Yasuhito Terui, Masahiro Yokoyama, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2021
Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCLShoko Marshall, Noriko Nishimura, Norihito Inoue, et al.
Experimental Hematology & Oncology|December 6, 2012
R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphomaYuko Mishima, Yasuhito Terui, Masahiro Yokoyama, et al.
Vox Sanguinis|May 25, 2026
Factors associated with aggregate formation in cold-stored plateletsSamantha Huang, Yuko Mishima, S Lawrence Bailey, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Blood|May 20, 2017
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluationNaoko Tsuyama, Seiji Sakata, Satoko Baba, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 9, 2017
Efficacy of chemotherapy in extremely elderly patients with diffuse large B-cell lymphomaAnna Takahashi, Yuko Mishima, Masahiro Yokoyama, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 28, 2005
[An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify]Hisakazu Nishimori, Shunji Takahashi, Eijiro Nagasaki, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 25, 2010
[Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I]Kyoko Ueda, Masahiro Yokoyama, Hiroaki Asai, et al.
International Journal of Hematology|December 28, 2022
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignanciesWataru Munakata, Kiyoshi Ando, Masahiro Yokoyama, et al.
Scientific Reports|August 22, 2023
Prognostic value of post-treatment serum soluble interleukin-2 receptor in newly diagnosed diffuse large B-cell lymphoma patients who achieved complete metabolic response following R-CHOP therapyYuko Shirouchi, Noriko Nishimura, Yuko Mishima, et al.
British Journal of Haematology|October 28, 2017
Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5<sup>+</sup> DLBCLYuko Mishima, Yasuhito Terui, Masahiro Yokoyama, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 23, 2021
Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCLShoko Marshall, Noriko Nishimura, Norihito Inoue, et al.
Experimental Hematology & Oncology|December 6, 2012
R-CHOP with dose-attenuated radiation therapy could induce good prognosis in gastric diffuse large B cell lymphomaYuko Mishima, Yasuhito Terui, Masahiro Yokoyama, et al.
Vox Sanguinis|May 25, 2026
Factors associated with aggregate formation in cold-stored plateletsSamantha Huang, Yuko Mishima, S Lawrence Bailey, et al.
Pageof 11